Search Results
Found 3 results
510(k) Data Aggregation
(161 days)
The Envision™ Blood Glucose Testing System is for the quantitative measurement of the concentration of glucose in capillary whole blood taken from the fingertip, ventral palm, dosal hand, upper arm, forearm, calf and/or thigh by diabetic patients or health care professionals as an aid in the management of diabetes. ENVISION™ Blood Glucose Testing System is for in vitro diagnostic use and is not to be used for the diagnosis of or screening of diabetes or for neonatal use. Alternate site testing should be done during steady- state times when glucose is not changing rapidly.
The ENVISION™ Monitor is an in vitro diagnostic device designed for measuring the concentration of glucose in whole blood, which is used with the ENVISION™ Test strip. The principle of the test replies upon a specific type of glucose in blood sample, the oxidase glucose that reacts to electrodes in the test strip. The test strip employs an electrochemical signal generation an electrical current that will stimulate a chemical reaction. This reaction is measured by the Meter and displayed as your blood glucose result.
This document describes the regulatory submission for the ENVISION™ Blood Glucose Test System. It focuses on demonstrating substantial equivalence to a predicate device rather than presenting a standalone study with specific acceptance criteria and detailed performance metrics as one might find for a novel device or AI/ML product.
As such, the information typically requested in your prompt (e.g., sample sizes for test/training sets, detailed ground truth establishment, MRMC studies, specific performance metrics like F1, accuracy, etc.) is not explicitly provided or applicable in the context of this 510(k) summary for a blood glucose monitor. Blood glucose monitoring systems are evaluated against established performance standards and predicate devices, which typically involve accuracy studies comparing device readings to a laboratory reference method.
However, I will extract and infer the closest available information based on the provided text.
1. Table of Acceptance Criteria and Reported Device Performance
The document does not explicitly state numerical acceptance criteria in a table format. Instead, it refers to the performance of the predicate device as the benchmark for "substantial equivalence." The reported device performance is a general statement of meeting this equivalence.
Performance Metric Type | Acceptance Criteria (Implied) | Reported Device Performance |
---|---|---|
Clinical Performance | Substantial equivalence to the predicate device (LifeScan One Touch® Ultra® Blood Glucose Monitoring System) validation for consumer use and professional accuracy. | "Test results showed substantial equivalence." |
Non-Clinical (Verification, Validation, Testing) | Pass/Fail criteria based on specifications cleared for the predicate device. | "Results showed substantial equivalence." |
Overall Conclusion | As safe, effective, and performs as well as the legally marketed predicate device. | "The ENVISION™ Blood Glucose Monitoring System is as safe, as effective, and performs as well as the legally marketed predicate device, the ONE TOUCH® Ultra®." |
2. Sample Sizes Used for the Test Set and Data Provenance
- Sample Size for Test Set: Not explicitly stated. The document refers to "clinical performance evaluation" without providing the number of subjects or samples.
- Data Provenance: Not specified (e.g., country of origin). The studies appear to be "prospective" in the sense that performance evaluations were conducted for the purpose of validating the consumer use for the user and the professional accuracy of the ENVISION™ system.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
This type of information is not provided because blood glucose monitoring systems typically use a laboratory reference method (e.g., a YSI analyzer) as the "ground truth" for glucose concentration, not expert consensus on images or other subjective data. No mention of experts for ground truth is made.
4. Adjudication Method for the Test Set
Not applicable. As described above, the "ground truth" for blood glucose measurements is typically an objective laboratory reference method, not an adjudicated expert opinion.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
Not applicable. MRMC studies are typically used for diagnostic imaging devices where human readers interpret medical images. This device is a blood glucose monitor.
6. Standalone (Algorithm Only Without Human-in-the-Loop Performance) Study
The device itself is a standalone system (monitor + test strips) that provides a direct glucose reading. The "clinical performance evaluation" assessed its accuracy against a reference, which is essentially a standalone performance assessment in a clinical setting. There is no "human-in-the-loop" in the interpretation of the numerical glucose result from the device.
7. The Type of Ground Truth Used
The ground truth implicitly used for accuracy assessments in blood glucose monitoring systems is a laboratory reference method for glucose measurement (e.g., using a YSI glucose analyzer). While not explicitly stated in the provided text, this is the standard practice for validating such devices. The document refers to "professional accuracy," which implies comparison to a highly accurate reference.
8. Sample Size for the Training Set
Not applicable. This device is a measurement system, not a machine learning model that requires a "training set" in the conventional sense. Its performance is based on the electrochemical reaction and calibrated sensor, not a learned algorithm from a large dataset.
9. How the Ground Truth for the Training Set Was Established
Not applicable, as there is no "training set" in the context of this blood glucose monitoring device.
Ask a specific question about this device
(90 days)
EnVision is a light-cured orthodontic bonding adhesive that is designed to be used for the attachment of orthodontic appliances to teeth.
The device is a chromatic orthodontic bonding adhesive. This single paste bonding adhesive initially has a blue color that enhances ease of use. Upon curing, the final color takes on the shade of the tooth, rendering it unnoticeable. Envision has an extended working time and has a very fast light cure property that achieves high strength, allowing active archwires to be placed immediately. EnVision is compatible with traditional etching and sealant procedures, as well as newer self-etching techniques
The provided text is a 510(k) summary and FDA clearance letter for the EnVision orthodontic bonding adhesive. It focuses on regulatory approval based on substantial equivalence to existing devices, product description, and intended use.
Crucially, this document does not contain any information regarding acceptance criteria, performance data, or a clinical study that would describe how the device meets such criteria. It's a regulatory document, not a scientific study report.
Therefore, I cannot provide the requested information from this text. The questions below would be answered with "information not found in the provided document."
Here is a breakdown of why each point cannot be addressed:
- A table of acceptance criteria and the reported device performance: This document does not specify any performance criteria (e.g., bond strength, cure time, discoloration limits) nor does it report the device's performance against such criteria. The clearance is based on substantial equivalence to predicate devices, implying similar performance is expected, but no specific data is presented.
- Sample sized used for the test set and the data provenance: No test set is described, as no performance study is detailed.
- Number of experts used to establish the ground truth for the test set and the qualifications of those experts: No ground truth establishment process for a test set is described.
- Adjudication method (e.g., 2+1, 3+1, none) for the test set: No test set or adjudication method is described.
- If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: This device is an orthodontic bonding adhesive, not an AI-powered diagnostic tool. Therefore, an MRMC study involving human readers and AI is not applicable.
- If a standalone (i.e., algorithm only without human-in-the-loop performance) was done: This device is a physical product (adhesive), not an algorithm. Standalone algorithm performance is not applicable.
- The type of ground truth used (expert consensus, pathology, outcomes data, etc.): No ground truth is described as no performance study is detailed.
- The sample size for the training set: No training set is applicable as this is not a machine learning device.
- How the ground truth for the training set was established: Not applicable.
Ask a specific question about this device
(36 days)
The Envision™ Anterior Cervical Plate System is intended for the treatment of the cervical spine in skeletally mature patients receiving fusion by autogenous and/or allogenic bone graft. The implants are attached to the anterior cervical spine (C2-T1) with removal of the implant after the attainment of a solid fusion mass. The Envision Anterior Cervical Plate System is intended for use under the following indications:
- Degenerative disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies)
- Spondylolisthesis
- Trauma (i.e., fracture)
- Tumor
- Deformity (i.e., kyphosis, lordosis, and scoliosis)
- Spinal stenosis
- Pseudarthrosis
- Failed previous fusion
The Ortho Development Envision Anterior Cervical Plate System system is a cervical spinal fixation device, which consists of a variety of bone plates and bone screws. Fixation is provided by the insertion of bone screws thought the openings at each end of the plate into the anterior portion of vertebral bodies of the cervical spine. The devices are manufactured from Ti-6Al-4V alloy per ASTM F-136. The Envision Anterior Cervical Plate System functions to provide a means to fuse the cervical spine.
The provided text describes a submission for the Ortho Development Envision Anterior Cervical Plate System. This is a medical device designed for cervical spinal fixation.
Here's an analysis of the acceptance criteria and study information, based on your request:
1. Table of Acceptance Criteria and Reported Device Performance
Acceptance Criteria Category | Specific Criteria/Test | Reported Device Performance |
---|---|---|
Biomechanical Performance | Static and fatigue compression testing per ASTM F1717-96 | Similar to the performance of previously cleared spinal systems with similar indications. |
Static torsion testing per ASTM F1717-96 | Similar to the performance of previously cleared spinal systems with similar indications. | |
Material Composition | Manufactured from Ti-6Al-4V alloy | Meets ASTM F-136 standard for Ti-6Al-4V alloy. |
2. Sample Size Used for the Test Set and Data Provenance
The provided documentation describes non-clinical performance testing (mechanical testing), not a test set based on patient data. Therefore, the concept of a "test set" in the context of clinical data provenance or sample size doesn't apply directly here. The testing was conducted on manufactured devices.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications of Those Experts
This question is not applicable. The assessment was based on mechanical testing results against an ASTM standard, not expert consensus on clinical cases.
4. Adjudication Method for the Test Set
This question is not applicable. The assessment was based on mechanical testing results, not a clinical adjudication process.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done
No, an MRMC comparative effectiveness study was not done. The submission explicitly states: "Clinical data and conclusion were not needed for this device."
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
This question is not applicable. The device is a physical medical implant, not a software algorithm.
7. The Type of Ground Truth Used
The ground truth used for the device's performance was compliance with a recognized industry standard (ASTM F1717-96 for mechanical testing). This standard defines accepted biomechanical performance characteristics for spinal fixation devices.
8. The Sample Size for the Training Set
This question is not applicable. The device is a physical medical implant, not an AI/ML algorithm. There is no concept of a "training set" in this context.
9. How the Ground Truth for the Training Set Was Established
This question is not applicable for the same reason as above. There is no training set for this type of device.
Overall Context of the Submission:
It's important to note that this document is a 510(k) premarket notification for a medical device. The primary method for demonstrating "substantial equivalence" in a 510(k) is often through comparison to legally marketed predicate devices and non-clinical testing (like biomechanical), rather than extensive new clinical trials, especially when the technology is well-established. The FDA's letter explicitly states that they found the device "substantially equivalent" to predicate devices and that clinical data was not needed for this particular submission.
Ask a specific question about this device
Page 1 of 1